

# Acute Lymphoblastic Leukemia (ALL) Treatment

Intensive Phase

Maintenance Therapy (MT)


Bi-weekly absolute neutrophil count and platelets check based on which oral chemotherapy drugs are prescribed

6 months

2 years




Electronic Health Records



MT Data Repository for Research Studies

1<sup>st</sup> of its own kind publicly available of ALL patients treated between 2013-2022



2020

In-person clinic was converted to hybrid mode clinic (In-person and E-mail clinic)

Continue data collection

Evidence for suboptimal MT



Strict adherence to treatment protocol

Pilot Study 2014-2016

2016-2019



Pill Reminder mobile application



Automated Dose Advice Method (ADAM) Clinical Decision Support System

PROTOTYPE tools for treatment protocol adherence

Currently in 2024, ADAM is undergoing real-time clinical validation


TOOLS for physicians to evaluate MT in real-time 2019-2023



allMT R Library for analyzing MT data Available on CRAN

VIATAMIN R application Hosted publicly

Survival Impact of 2024 Standardised ALL Maintenance Treatment Practice



Drug dose intensity	Patients	Survival (%)	95% CI	$p^*$
< 80% of protocol dose	117	60	51-69	0.041
≥ 80% of protocol dose	93	75	65-83	

Tata Medical Center paediatric ALL patients diagnosed between 8/2013 & 7/2017  
 Event-free survival, 5 years from ALL maintenance start; 95% confidence interval; \*2-sided log-rank

Event includes relapse or treatment-related death